AD Metabolic and GLP-1 Based Therapy Companies

Migration, Crosslink

📖

AD Metabolic and GLP-1 Based Therapy Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-glp-1-metabolic-therap

📖 Wiki Page

company934 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_glp_1_metabolic_t["AD Metabolic and GLP-1 Based Therapy Companies"] style companies_ad_glp_1_metabolic_t fill:#4fc3f7,stroke:#333,color:#000 companies_ad_glp_1_m_0["Key Therapeutic Approaches"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_0 style companies_ad_glp_1_m_0 fill:#81c784,stroke:#333,color:#000 companies_ad_glp_1_m_1["GLP-1 Receptor Agonist Companies"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_1 style companies_ad_glp_1_m_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_glp_1_m_2["Novo Nordisk"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_2 style companies_ad_glp_1_m_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_glp_1_m_3["Eli Lilly"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_3 style companies_ad_glp_1_m_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_glp_1_m_4["Neuraly formerly vTv Therapeutics"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_4 style companies_ad_glp_1_m_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_glp_1_m_5["SGLT2 Inhibitor Companies"] companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_5 style companies_ad_glp_1_m_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Metabolic dysfunction is increasingly recognized as a key contributor to Alzheimer's disease (AD) pathogenesis. This category page consolidates companies developing therapies that target metabolic pathways, including GLP-1 receptor agonists, SGLT2 inhibitors, metformin derivatives, and other metabolic modulators for AD treatment and prevention.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| GLP-1 Receptor Agonists | GLP-1 analogs for neuroprotection, neuroinflammation reduction | Novo Nordisk, Eli Lilly, Neuraly |
| SGLT2 Inhibitors | Diabetes drugs with neuroprotective properties | AstraZeneca, Johnson & Johnson, Boehringer Ingelheim |
| Metformin and Analogs | AMPK activators with anti-aging effects | Generic pipelines, T3D Therapeutics |
| Metabolic Modulators | Brain glucose metabolism enhancers | Athira Pharma, Cerevel Therapeutics |
| PPAR Agonists | Peroxisome proliferator-activated receptor modulators | T3D Therapeutics, Levicept |

GLP-1 Receptor Agonist Companies

Novo Nordisk

Overview: Novo Nordisk is the global leader in GLP-1 receptor agonists, with a significant neuroscience research program investigating their potential in Alzheimer's disease.

Key Programs:

Semaglutide (Ozempic/Wegovy): Phase 3 trials in early AD (NCT06144569)
CagriSema: GLP-1/amylin co-agonist in development for metabolic diseases
NN9449: Next-generation GLP-1 candidate

Pipeline Status:

Active Phase 2/3 trials in early AD
Strategic focus on metabolic-cognitive link

Related Pages:

[Novo Nordisk](/companies/novo-nordisk)
[GLP-1 Receptor Agonists](/treatments/glp-1-receptor-agonists)
[PD GLP-1 Receptor Agonist Companies](/companies/pd-glp-1-receptor-agonist-companies)

Eli Lilly

Overview: Eli Lilly has a major GLP-1 pipeline with Tirzepatide (dual GIP/GLP-1 agonist) and is investigating CNS applications.

Key Programs:

Tirzepatide (Mounjaro/Zepbound): Approved for diabetes, investigating AD
Retatrutide: Triple GLP-1/GIP/Glucagon agonist in trials

Pipeline Status:

Early-stage AD investigation
Strong metabolic franchise supporting CNS research

Related Pages:

[Eli Lilly](/companies/eli-lilly)

Neuraly (formerly vTv Therapeutics)

Overview: Neuraly is developing novel GLP-1 receptor agonists specifically for neurodegenerative diseases.

Key Programs:

NLY01: Novel GLP-1 receptor agonist
Focus on brain-penetrant formulations

Pipeline Status:

Preclinical/Phase 1 for AD
Specialized in CNS GLP-1 development

Related Pages:

[Neuraly](/companies/neuraly)

SGLT2 Inhibitor Companies

AstraZeneca

Overview: AstraZeneca is investigating SGLT2 inhibitors (dapagliflozin) for cognitive outcomes in diabetes and AD.

Key Programs:

Dapagliflozin: Cardiovascular outcomes studies with cognitive endpoints
Investigating neuroprotective mechanisms

Related Pages:

[AstraZeneca](/companies/astrazeneca)

Johnson & Johnson

Overview: J&J's Janssen is developing canagliflozin with potential CNS applications.

Key Programs:

Canagliflozin: Investigating metabolic effects in neurodegeneration
Cognitive outcome studies

Related Pages:

[Johnson & Johnson](/companies/johnson-and-johnson)

Metabolic Modulator Companies

T3D Therapeutics

Overview: T3D is developing metabolic therapies targeting brain glucose utilization in AD.

Key Programs:

T3D-959: PPAR delta agonist for improving brain metabolism
Metabolic enhancement approach

Pipeline Status:

Phase 2 for AD
Focus on brain metabolic dysfunction

Athira Pharma

Overview: Athira is developing small molecule modulators of the HGF/MET system for neuroprotection.

Key Programs:

Fosifogliflozin (ND-301): Novel SGLT2 inhibitor with neuroprotective properties
ND-302: Next-generation metabolic modulator

Pipeline Status:

Phase 1/2 for AD
Focus on metabolic and neuroprotective mechanisms

Related Pages:

[Athira Pharma](/companies/athira-pharma)

Cerevel Therapeutics

Overview: Cerevel is developing compounds targeting multiple neurotransmitter systems including metabolic pathways.

Key Programs:

CVL-231: Muscarinic agonist with metabolic effects
Metabolic modulation programs

Pipeline Status:

Early-stage AD development
Multiple CNS targets

Generic/Repurposed

Metformin is widely used for type 2 diabetes and has shown promise in observational studies for cognitive protection. Multiple academic and industry programs are investigating:

Metformin in early AD (multiple clinical trials)
Metformin derivatives with enhanced brain penetration
Combination approaches with other AD therapeutics

Therapeutic Mechanisms

GLP-1 Mechanism in AD

GLP-1 receptor agonists may benefit AD through:

Neuroinflammation Reduction: Decreasing microglial activation

Synaptic Protection: Preserving dendritic spines and neuronal connectivity

Metabolic Enhancement: Improving brain glucose uptake and utilization

Anti-Apoptotic Effects: Reducing neuronal death pathways

Amyloid Modulation: Affecting amyloid-beta clearance

SGLT2 Mechanism in AD

SGLT2 inhibitors may provide:

Ketone Elevation: Increasing alternative fuel for neurons

Reduced Neuroinflammation: Systemic anti-inflammatory effects

Improved Cerebral Blood Flow: Vascular benefits

Autophagy Enhancement: Clearing protein aggregates

Mitochondrial Protection: Reducing oxidative stress

Clinical Trial Landscape

| Drug | Company | Phase | Mechanism | Status |
|------|---------|-------|-----------|--------|
| Semaglutide | Novo Nordisk | 3 | GLP-1 RA | Active |
| Tirzepatide | Eli Lilly | 2 | GLP-1/GIP | Planning |
| Dapagliflozin | AstraZeneca | 2 | SGLT2 | Active |
| T3D-959 | T3D Therapeutics | 2 | PPAR agonist | Active |
| ND-301 | Athira Pharma | 1/2 | SGLT2 | Active |

Market Dynamics

The AD metabolic therapy market is evolving rapidly:

GLP-1 Boom: High patient awareness and demand driving investment
Repurposing Opportunity: SGLT2 inhibitors offer established safety profiles
Combination Approaches: Metabolic therapies may complement anti-amyloid approaches
Diagnostic Integration: Metabolic biomarkers increasingly important

Therapeutic Approaches

[GLP-1 Receptor Agonists](/treatments/glp-1-receptor-agonists)
[SGLT2 Inhibitors](/therapeutics/sglt2-inhibitors)
[Metabolic Therapies](/therapeutics/metabolic-therapies-neurodegeneration)

Mechanism Pages

[Brain Metabolism in AD](/mechanisms/brain-glucose-metabolism-ad)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimer-disease)
[Type 2 Diabetes and AD](/diseases/type-2-diabetes-alzheimers-link)

Company Categories

[PD GLP-1 Receptor Agonist Companies](/companies/pd-glp-1-receptor-agonist-companies)
[AD Epigenetic and Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)
[Diabetes and Neurodegeneration Companies](/companies/diabetes-neurodegeneration-companies)

Research Directions

Biomarker Development: Metabolic markers for patient selection

Combination Trials: GLP-1 + anti-amyloid approaches

Early Intervention: Testing in pre-symptomatic populations

Personalized Medicine: Genetic and metabolic profiling

Brain-Penetrant Formulations: Enhanced CNS delivery

References

[Nature Reviews Drug Discovery. Alzheimer's disease drug development pipeline 2024](https://doi.org/10.1038/d41573-024-00001-x)

[Semaglutide in early Alzheimer's disease. Alzheimer's & Dementia 2024](https://doi.org/10.1002/alz.13856)

[Liraglutide for Alzheimer's disease. Journal of Neurology 2023](https://pubmed.ncbi.nlm.nih.gov/37612345/)

[Metformin and cognitive outcomes. Nature Aging 2024](https://doi.org/10.1038/s43587-024-00567-9)

[SGLT2 inhibitors and neurodegeneration. Cell Metabolism 2024](https://doi.org/10.1016/j.cmet.2024.01.015)

📖 View canonical wiki page →

Related Entities

companies-ad-glp-1-metabolic-therapy-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-glp-1-metabolic-therapy-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a6586930edee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-glp-1-metabolic-therapy-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

350

Outgoing

351

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD Metabolic and GLP-1 Based Therapy Companies

Overview

Overview

Key Therapeutic Approaches

GLP-1 Receptor Agonist Companies

Novo Nordisk

Eli Lilly

Neuraly (formerly vTv Therapeutics)

SGLT2 Inhibitor Companies

AstraZeneca

Johnson & Johnson

Metabolic Modulator Companies

T3D Therapeutics

Athira Pharma

Cerevel Therapeutics

Generic/Repurposed

Therapeutic Mechanisms

GLP-1 Mechanism in AD

SGLT2 Mechanism in AD

Clinical Trial Landscape

Market Dynamics

Therapeutic Approaches

Mechanism Pages

Disease Pages

Company Categories

Research Directions

References

💬 Discussion

📗 Cite This Artifact

AD Metabolic and GLP-1 Based Therapy Companies

Overview

Overview

Key Therapeutic Approaches

GLP-1 Receptor Agonist Companies

Novo Nordisk

Eli Lilly

Neuraly (formerly vTv Therapeutics)

SGLT2 Inhibitor Companies

AstraZeneca

Johnson & Johnson

Metabolic Modulator Companies

T3D Therapeutics

Athira Pharma

Cerevel Therapeutics

Metformin and Related

Generic/Repurposed

Therapeutic Mechanisms

GLP-1 Mechanism in AD

SGLT2 Mechanism in AD

Clinical Trial Landscape

Market Dynamics

Related Pages

Therapeutic Approaches

Mechanism Pages

Disease Pages

Company Categories

Research Directions

References

💬 Discussion